Patents by Inventor Chandrakant Dhatrak

Chandrakant Dhatrak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE
    Publication number: 20180000844
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Inventors: Ulhas R Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE
    Publication number: 20180000841
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • TIOTROPIUM INHALATION SOLUTION FOR NEBULIZATION
    Publication number: 20170326117
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Inventors: Ulhas DHUPPAD, Franciscus KOPPENHAGEN, Sunil CHAUDHARI, Suresh RAJURKAR, Chandrakant DHATRAK, Alkesh KASLIWAL
  • Tiotropium inhalation solution for nebulization
    Patent number: 9757365
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: September 12, 2017
    Assignee: Glenmark Specialty S.A.
    Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
    Patent number: 9750754
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: September 5, 2017
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR
    Publication number: 20170135991
    Abstract: The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in a subject.
    Type: Application
    Filed: July 31, 2015
    Publication date: May 18, 2017
    Inventors: Ulhas R. DHUPPAD, Sunil CHAUDHARI, Suresh RAJURKAR, Nilesh JAIN, Chandrakant DHATRAK, Alkesh KASLIWAL
  • TIOTROPIUM INHALATION SOLUTION FOR NEBULIZATION
    Publication number: 20160339003
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Application
    Filed: May 17, 2016
    Publication date: November 24, 2016
    Inventors: Ulhas DHUPPAD, Franciscus KOPPENHAGEN, Sunil CHAUDHARI, Suresh RAJURKAR, Chandrakant DHATRAK, Alkesh KASLIWAL
  • STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE
    Publication number: 20160287612
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Application
    Filed: June 15, 2016
    Publication date: October 6, 2016
    Inventors: Ulhas R. DHUPPAD, Ashok KATKURWAR, Yashwant GUPTA, Rajesh ANKAM, Chandrakant DHATRAK
  • Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
    Patent number: 9370483
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 21, 2016
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE
    Publication number: 20150250718
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Application
    Filed: March 18, 2015
    Publication date: September 10, 2015
    Inventors: Ulhas R. DHUPPAD, Ashok KATKURWAR, Yashwant GUPTA, Rajesh ANKAM, Chandrakant DHATRAK
  • Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
    Patent number: 9078923
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: July 14, 2015
    Assignee: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Ulhas Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE
    Publication number: 20150079178
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 19, 2015
    Inventors: Ulhas DHUPPAD, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak